Who is sponsoring NCT05325242?

NCT05325242 is sponsored by Siddharth Padia, MD.

What drugs are being tested in NCT05325242?

Interventions in NCT05325242: Embozene particles.

What condition does NCT05325242 study?

NCT05325242 studies Lateral Epicondylitis, Unspecified Elbow.

Is NCT05325242 still recruiting?

NCT05325242 is currently recruiting now. Last updated 23 March 2026.

Last reviewed 2026-03-23 · How we verify

NCT05325242

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Elbow Artery Embolization for Tennis Elbow

Recruiting now NA Last updated 23 March 2026

What this trial tests

NA trial testing Embozene particles in Lateral Epicondylitis, Unspecified Elbow in 25 participants. Currently enrolling.

Timeline

21 March 2023

Primary endpoint
31 December 2027

31 December 2027

Quick facts

Lead sponsor	Siddharth Padia, MD
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	25
Start date	21 March 2023
Primary completion	31 December 2027
Estimated completion	31 December 2027
Sites	1 location across United States

Drugs / interventions tested

Embozene particles

Conditions studied

Lateral Epicondylitis, Unspecified Elbow — all drugs for Lateral Epicondylitis, Unspecified Elbow →

Sponsor

Siddharth Padia, MD

Who can join

18 and older, any sex, with Lateral Epicondylitis, Unspecified Elbow. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this clinical research study is to examine whether embolization treatment of an elbow artery is a safe and effective way to treat elbow pain, specifically pain from tennis elbow. Embozene is a medical device made by Varian marketed in the United States for the treatment of hypervascular tumors and arteriovenous malformations. It consists of thousands of microscopic spheres that are injected into the artery to block the flow of blood to a specific region. One of the causes of pain in the setting of tennis elbow is increased blood flow going to the specific area of pain. In this study, we will investigate an experimental procedure to decrease the blood flow (embolize) to the specific region of the elbow that is causing the pain. This will be done by infusing Embozene particles into the specific blood vessel supplying the area of pain in the elbow. This is an investigational study to evaluate the safety and efficacy of elbow artery embolization (EAE) for the treatment of symptomatic lateral epicondylitis (tennis elbow).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Lateral Epicondylitis, Unspecified Elbow

Currently open trials in the same condition.

NCT06490692 — The Effect of Blood Flow Restriction Training on Tennis Elbow · NA · recruiting

Other Siddharth Padia, MD trials

Trials by the same sponsor.

NCT03491397 — Genicular Artery Embolization for the Treatment of Knee Osteoarthritis · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05325242 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Siddharth Padia, MD
Last refreshed: 23 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05325242.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing